Hewitt Judith A, Brown Liliana L, Murphy Stephanie J, Grieder Franziska, Silberberg Shai D
Office of Biodefense, Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD. Office of Genomics and Advanced Technologies, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD. Division of Comparative Medicine, Office of Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director at the National Institutes of Health, Bethesda, MD. Office of Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, MD. National Institute of Neurological Disorders and Stroke, Bethesda MD.
ILAR J. 2017 Jul 1;58(1):115-128. doi: 10.1093/ilar/ilx011.
Difficulties in reproducing published research findings have garnered a lot of press in recent years. As a funder of biomedical research, the National Institutes of Health (NIH) has taken measures to address underlying causes of low reproducibility. Extensive deliberations resulted in a policy, released in 2015, to enhance reproducibility through rigor and transparency. We briefly explain what led to the policy, describe its elements, provide examples and resources for the biomedical research community, and discuss the potential impact of the policy on translatability with a focus on research using animal models. Importantly, while increased attention to rigor and transparency may lead to an increase in the number of laboratory animals used in the near term, it will lead to more efficient and productive use of such resources in the long run. The translational value of animal studies will be improved through more rigorous assessment of experimental variables and data, leading to better assessments of the translational potential of animal models, for the benefit of the research community and society.
近年来，难以重复已发表的研究结果这一问题受到了大量媒体关注。作为生物医学研究的资助者，美国国立卫生研究院（NIH）已采取措施来解决重复性低的根本原因。广泛的审议促成了一项于2015年发布的政策，该政策旨在通过严谨性和透明度来提高研究的可重复性。我们简要解释该政策的出台背景，描述其内容，为生物医学研究界提供实例和资源，并讨论该政策对可转化性的潜在影响，重点关注使用动物模型的研究。重要的是，虽然短期内对严谨性和透明度的更多关注可能会导致实验动物使用数量增加，但从长远来看，这将使这些资源得到更高效和富有成效的利用。通过对实验变量和数据进行更严格的评估，动物研究的转化价值将得到提升，从而更好地评估动物模型的转化潜力，造福研究界和社会。
